Document:

EX-10.9

 Exhibit 10.9 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 LICENSE AGREEMENT 
 BETWEEN 

RESEARCH DEVELOPMENT FOUNDATION 
 AND 
 BLUEBIRD BIO, INC. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 TABLE OF CONTENTS 

 

			
	 	  	 Page

		
	 ARTICLE I Definitions
	  	1
		
	 ARTICLE II Grant of License
	  	3
	 Scope of License
	  	3
	 Right to Sublicense
	  	3
	 Retained Rights
	  	3
	 Government Rights
	  	3
		
	 ARTICLE III Patents
	  	4
	 Patent Applications
	  	4
	 Patent Prosecution and Maintenance
	  	4
	 Patent Costs
	  	4
		
	 ARTICLE IV Royalties and Other Consideration
	  	4
	 License Fee
	  	4
	 Royalty
	  	4
	 Basis of Royalty Obligation
	  	5
	 Limitation on Deductions from Royalty Payments
	  	5
	 Milestone Payments
	  	5
	 Marketing Arrangements
	  	5
		
	 ARTICLE V Reports and Payments
	  	5
	 Progress Reports
	  	5
	 Notice of Commercial Sale
	  	5
	 Royalty Reports and Payments
	  	6
	 U.S. Dollars
	  	6
	 Report on Termination
	  	6
	 Books and Records
	  	6
	 Delinquent Payments
	  	7
		
	 ARTICLE VI Diligence; Minimum Royalties
	  	7
		
	 ARTICLE VII Protection of Patents
	  	8
	 Protection
	  	8
	 Notice of Infringement; Licensor Enforcement of Third Party Infringement
	  	8
	 Notice of Infringement; Claim of Licensee Infringement
	  	8
	 Reasonable Assistance
	  	8
	 Declaratory Judgment Actions
	  	8
	 Patent Certifications
	  	8

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

			
	 ARTICLE VIII Disclaimer of Liability and/or Warranty
	  	8
	 No Warranty
	  	8
	 No Damages
	  	9
	 No Warranty of Quality or Usefulness
	  	9
	 Indemnification
	  	9
	 Insurance
	  	9
		
	 ARTICLE IX Term; Termination
	  	9
	 Term
	  	9
	 Termination for Cause; Insolvency
	  	10
	 Default
	  	10
	 Commercialization Rights Upon Termination
	  	10
	 Provisions Surviving Termination
	  	10
		
	 ARTICLE X Representations and Warranties
	  	11
	 Warranty to Title
	  	11
	 Power and Authority
	  	11
	 Compliance with Laws
	  	11
	 No Knowledge of Infringement
	  	11
		
	 ARTICLE XI Agency/Partnership/Use of Name
	  	11
	 No Agency
	  	11
	 No Partnership
	  	11
	 Prohibition Against Use of Name
	  	11
		
	 ARTICLE XII Marking
	  	12
		
	 ARTICLE XIII Nondisclosure of Confidential Information
	  	12
		
	 ARTICLE XIV Miscellaneous
	  	13
	 Captions
	  	13
	 Notices
	  	13
	 Assignment
	  	13
	 No Waiver
	  	13
	 Choice of Law and Jurisdiction
	  	14
	 Severability
	  	14
	 Further Acts
	  	14
	 Entire Agreement
	  	14
	 Successors and Assigns
	  	14
		
	 EXHIBIT 1
	  	
	 Licensed Patents
	  	
		
	 EXHIBIT 2
	  	
	 Milestone Payments
	  	

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 LICENSE AGREEMENT 

This License Agreement (hereinafter referred to as “Agreement”) is made and entered into as of the 7th day of December, 2011
(the “Effective Date” of this Agreement), by and between RESEARCH DEVELOPMENT FOUNDATION (hereinafter referred to as “Licensor”), a Nevada nonprofit corporation having its office at 402 North Division Street, Carson City, Nevada,
89703; 
 AND 

BLUEBIRD BIO, INC., having an office at 840 Memorial Drive, Cambridge, Massachusetts, 02139 (hereinafter referred to as “Licensee”).

 WITNESSETH: 
 WHEREAS, Licensor is a nonprofit organization exempt from taxation under Section 501(c)(3) of the Internal Revenue Code of 1986; 

WHEREAS, Licensor is the owner of “Licensed Patents” (as defined below); 

WHEREAS, Licensor has determined that the grant of a license to Licensee is the only practicable manner in which the Licensed Patents can
be utilized to benefit the public; 
 WHEREAS, Licensee desires to obtain a [***] license from Licensor as described herein, and
Licensor desires to grant such a license pursuant to the terms and conditions of this Agreement; 
 NOW, THEREFORE, in
consideration of the above premises and the covenants herein, the parties agree as follows: 
 ARTICLE I 

Definitions 
 As used in this Agreement, the following capitalized terms shall have the following respective meanings: 
 1.1 The term “Licensed Patents” shall mean the United States and foreign patent applications and issued patents listed in Exhibit 1, including all continuations, continuations-in-part,
divisionals, patents of addition, reissues, renewals or extensions (including supplementary protection certificates) and all foreign counterparts of the foregoing. 
 1.2 The term “Licensed Product” shall mean any process, method, material, composition, drug, or other product or portion of a product within a Valid Claim of the Licensed Patents. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 1.3 The term “Make, Use or Sell” shall mean to develop, have developed,
produce, have produced, make, have made, manufacture, have manufactured, use, have used, offer for sale, have offered for sale, sell, have sold, rent, have rented, lease, have leased, import or have imported a Licensed Product. 

1.4 The term “Affiliate” shall mean any present or future companies, corporations, partnerships, joint ventures, business
trusts or other business entities organized under the laws of any nation (a) with respect to which: (i) at least fifty percent (50%) in value of the total equity interests, (ii) at least fifty percent (50%) of the total
combined voting power of all classes of shares entitled to vote, or (iii) at least fifty percent (50%) of the profits interest in the case of a partnership, joint venture or other non-stock entity, is directly or indirectly under the
control of Licensee, or (b) with respect to which Licensee has effective control, directly or indirectly. “Control” shall mean the possession of the power to direct or cause the direction of the management and the policies of an
entity, whether through an ownership interest or by contract or otherwise. The term “Licensee” wherever used herein shall include any Affiliate of Licensee. 
 1.5 The term “Net Sales” shall mean the gross amount received with respect to the sale or other transfer of Licensed Product, less the following deductions for amounts actually incurred related
to such sale or other transfer and included in the gross invoiced amount: (a) normal, customary trade discounts (including volume discounts), credits and rebates, and allowances and adjustments for rejections, recalls, returns or retroactive
price reductions; and (b) freight, insurance, sales, use, excise, value-added and similar taxes or duties imposed on the sale. 
 No other allowance or deduction shall be made by whatever name known. For the avoidance of doubt, transfers of a Licensed Product between any of Licensee, an Affiliate or a sublicensee for sale by the
transferee shall not be considered Net Sales hereunder. 
 1.6 The terms “commercialize” and
“commercialization” shall mean the Making, Using, or Selling, licensing or other use by Licensee (or a sublicensee) of the Licensed Product under such circumstances as may be permitted by applicable international, federal, and state laws
and regulation. 
 1.7 The term “Valid Claim” shall mean, in the country of manufacture or sale, (a) a claim of
any issued and unexpired patent within the Licensed Patents that (i) has not been permanently revoked, nor held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction that is
unappealable or unappealed in the time allowed for appeal, (ii) has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, and (iii) has not been lost through an interference, reexamination, post-grant
review or reissue proceeding; or (b) a pending claim of a pending patent application included in the Licensed Patents that was filed and has been prosecuted in good faith and has not been (i) cancelled, withdrawn, abandoned or finally
disallowed without the possibility of appeal or refiling of such application, or (ii) pending for more than [***] since such claim was first presented; provided, however, that such claim pending for more than [***] shall be a Valid Claim if and
when it is issued as a claim of an issued and unexpired patent included within Licensed Patents, or if it is part of an opposition, interference, re-examination or other such administrative proceeding. 

1.8 The term “Cover(s)” or “Covered” or “Covering” shall mean that a product, process, material,
composition, drag, or other product or portion of a product would infringe a Valid Claim in a Licensed Patent (or in the case of a Valid Claim in a patent application within the Licensed Patents, would infringe such Valid Claim if it were in an
issued patent) but for the exclusive license granted to Licensee hereunder. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 ARTICLE II 
 Grant of License 
 2.1 Scope of License. Licensor hereby grants and
Licensee hereby accepts a [***], exclusive license under the Licensed Patents to Make, Use or Sell Licensed Products. Except as provided herein, no other, further, or different license is hereby granted, either expressly or by implication.

 2.2 Right to Sublicense. Licensor hereby grants and Licensee hereby accepts the right to grant sublicenses through
multiple tiers to third parties to all or any portion of Licensee’s rights hereunder. Licensee shall, within thirty (30) days of the grant of each such sublicense, give written notice of such sublicenses to Licensor and provide Licensor
with a copy thereof; provided that Licensee may redact those portions of such sublicenses that are not necessary for Licensor to determine whether Licensee is in compliance with its obligations under this Agreement. Licensee shall incorporate terms
and conditions into its sublicense agreements sufficient to enable Licensee to comply with this Agreement. Upon termination of this Agreement for any reason, Licensor shall grant to a sublicensee that is not in material breach of its sublicense a
direct license granting rights and terms equivalent to the sublicense rights and terms which Licensee previously granted to such sublicensee, provided that Licensor shall have no greater rights and obligations to any such sublicensee than Licensor
has to Licensee under this Agreement. 
 2.3 Retained Rights. Licensor retains the right, on behalf of itself and other
nonprofit academic research institutions, to practice and use the Licensed Patents for any academic, non-clinical research and educational purposes. Licensee agrees that, notwithstanding any other provision of this Agreement, it has no right to
enforce the Licensed Patents against any such practice or use by any such institution. 
 2.4 Government Rights. If any
invention described and claimed in the Licensed Patents is developed with the support of federal research funds, Title 35, Sections 200-212 of the United States Code (the “Bayh-Dole Act”) shall apply. Among other things, the provisions of
the Bayh-Dole Act provide the United States Government with non-exclusive rights in any inventions arising from the use of federal funds and also generally impose the obligation that any products embodying the subject invention or produced through
the use of such invention be manufactured substantially in the United States. If and to the extent the Bayh-Dole Act is 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
applicable to any Licensed Patents, Licensee acknowledges and agrees that the rights granted under this Agreement are subject to the applicable terms and conditions of the Bayh-Dole Act and that
Licensee will ensure that all relevant obligations under the Bayh-Dole Act provisions are met. 
 ARTICLE III 

Patents 

3.1 Patent Applications. Licensor represents that it has timely filed patent applications relating to the Licensed Patents in the
countries listed on Exhibit 1 hereto. 
 3.2 Patent Prosecution and Maintenance. Licensor will control the conduct,
preparation, filing and prosecution of such patent applications within the Licensed Patents and will maintain any patents issued thereon, but will provide Licensee with copies of all office actions and responses thereto and will consider and take
into account in good faith Licensee’s comments with respect thereto. Notwithstanding the foregoing sentence, in the event that Licensor within its sole judgment and discretion determines that prosecution or maintenance of a patent in a
particular country is not economically viable or otherwise feasible, Licensor shall promptly notify Licensee of Licensor’s intention to abandon such patent application or patent. Upon receipt of such notice, Licensee, in its sole discretion,
may elect to assume responsibility (and to pay associated fees and expenses) with respect to a patent application or patent which Licensor intends to abandon. Licensee may, in its sole discretion, abandon any patent application or patent for which
it has previously assumed responsibility and will not be liable to Licensor in any way for such abandonment. 
 3.3 Patent
Costs. Licensee shall reimburse Licensor for [***] for filing, prosecuting and maintaining the Licensed Patents. Licensor shall invoice Licensee for such patent costs quarterly, and undisputed payments shall be made by Licensee within thirty
(30) days after receipt of each invoice. 
 ARTICLE IV 

Royalties and Other Consideration 
 4.1 License Fee. Licensee shall pay Licensor an up-front non-refundable license fee of [***] within ten (10) business days after the execution of this Agreement by the parties. 

4.2 Royalty. Licensee shall pay Licensor an earned royalty of [***] on Net Sales of Licensed Product, on a Licensed
Product-by-Licensed Product and country-by-country basis, where there is at least one Valid Claim of a Licensed Patent Covering such Licensed Product in such country at the time of first marketing approval. Such royalty shall continue until the
longer of: (a) expiry or end of the last Valid Claim within a Licensed Patent that Covers a Licensed Product in such country, or (b) ten (10) years from the first marketing approval; provided that the royalty shall be reduced by [***]
if payable under this clause (b) after the last Valid Claim 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
expires or ends during such ten (10) year period. For clarity, no royalty shall be owed on any Licensed Product not Covered by a Valid Claim under a Licensed Patent at the time of first
marketing approval in the country in question, and further, under no circumstances shall any royalty be owed (during the term of this Agreement or thereafter) if all the Valid Claim(s) that Cover a Licensed Product in a country are held not valid,
unenforceable or otherwise unpatentable. For clarity, in such event, royalties already paid by Licensee shall not be refunded by Licensor. Only one (1) royalty shall be payable on a Licensed Product, regardless of the number of Valid Claims or
the number of patent applications and patents within the Licensed Patents under which such Licensed Product has been Made, Used or Sold. 
 4.3 Basis of Royalty Obligation. Royalty payments to be paid at the applicable rate(s) hereunder shall be paid on a Licensed Product by Licensed Product and country-by-country basis. 

4.4 Limitation on Deductions from Royalty Payments. Wherever this Agreement provides that Licensee may deduct expenses, payments
or other amounts from royalties payable to Licensor, such deduction shall be prorated over such time as is necessary to assure that the royalties payable to Licensor in any period shall not be reduced by more than [***]. 

4.5 Milestone Payments. In addition to the up-front license fee and royalties required under this Article IV, Licensee shall make
milestone payments to Licensor as set forth in Exhibit 2 hereto. Such cash payments shall be delivered to Licensor within forty-five (45) days after the end of the calendar quarter in which each of the milestone payment events indicated on such
exhibit occurs. 
 4.6 Marketing Arrangements. Where Licensed Products are sold by a third party other than Licensee or
sublicensee under any type of commercial arrangement between Licensee (or sublicensee) and such third party (including, without limitation, a joint venture, distributorship, or collaboration agreement), Net Sales for earned royalty purposes shall be
calculated based on the gross sales of Licensed Products by such third party. 
 ARTICLE V 

Reports and Payments 
 5.1 Progress Reports. Licensee agrees to make an annual report to Licensor each March covering Licensee’s (and its sublicensees’, if applicable) progress during the previous calendar year
toward research, development, commercialization and out-licensing of Licensed Products. Email communication shall suffice for the purpose of this reporting requirement. 
 5.2 Notice of Commercial Sale. Licensee shall notify Licensor, in writing, within thirty (30) days of the date of the first commercial sale of a Licensed Product to a third party by Licensee
or a sublicensee. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 5.3 Royalty Reports and Payments. Licensee agrees that Licensor shall, if
applicable, receive within forty-five (45) days after the end of each quarter of each calendar year: 
  

	 	(a)	a complete and accurate royalty report showing the information and basis on which such amounts have been calculated, including disclosure of at least the following
information: 

  

	 	i.	[***]; 

  

	 	ii.	[***]; 

  

	 	iii.	[***]; 

  

	 	iv.	[***]; and 

  

	 	(b)	payment of amounts due to Licensor pursuant to this Agreement, including, but not limited to, amounts pursuant to Articles IV and VI. 

5.4 U.S. Dollars. All amounts payable by Licensee shall be paid in U.S. Dollars. Conversion from currencies other than U.S.
Dollars shall be at the rate of exchange used by Licensee for its general accounting purposes, consistent with generally accepted accounting principles. 
 5.5 Report on Termination. Licensee also agrees to make a written report to Licensor within ninety (90) days after the expiration or termination of this Agreement, stating in such report the
amounts payable hereunder and the basis therefor not previously reported to Licensor. In the event of a termination prior to expiration of the Term, Licensee shall also continue to make annual reports pursuant to the provisions of this Agreement
covering sales, uses, or production and the applicable earned royalties and other amounts payable hereunder for Licensed Products made during the Term, but not used or sold until after termination thereof, until such time as all such makings, uses
or sales shall have terminated. Concurrent with the submittal of such post-expiration or post-termination report, Licensee shall pay Licensor all applicable royalties and other amounts payable hereunder. 

5.6 Books and Records. Licensee shall keep full, true, clear and accurate records and books of account with respect to the
Licensed Products subject to royalty or other payments hereunder. Said records and books of account shall be kept by Licensee at the usual places where its like records and books are kept and shall be retained for a period of three (3) years
following the end of the calendar year to which they pertain. Licensor shall have the right through an independent public accountant selected by Licensor and reasonably acceptable to Licensee to examine and inspect during normal business hours all
such records and books of account and such other records and accounts as may under recognized accounting practices contain information reasonably bearing upon the amounts payable to it under this Agreement. Prompt adjustment shall be made by the
proper party to compensate for any errors or omissions disclosed by such examination or inspection. In the event the examination or inspection results 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
in a discrepancy in the correctness of the payments due under this Agreement in an amount in excess of [***] of the payments due Licensor for any single quarter audited, Licensee shall reimburse
Licensor for all reasonable out-of-pocket costs and fees associated with such examination or inspection, and all reasonable out-of-pocket costs and expenses required to collect the amount underpaid, including (but not limited to) reasonable
attorneys’ fees incurred in connection therewith. Neither such right to examine and inspect nor the right to receive such adjustment shall be affected by any statement to the contrary appearing on checks or otherwise, unless such statements
appear in a letter, signed by the party having such right and delivered to the other party, expressly waiving such right. Notwithstanding the foregoing, Licensor may require Licensee to furnish any other information reasonably requested to enable
Licensor to evaluate Licensee’s performance in accordance with this Agreement. 
 5.7 Delinquent Payments. Payments
provided for in this Agreement shall, when overdue, bear interest [***] per annum until paid, but in no event shall such interest exceed the usury limit, if any, as may exist from time to time in the State of Nevada. Each such payment when made
shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of Licensor to seek any other remedy, legal or equitable, to which it may be entitled because of the
delinquency of any payment or any other breach of this Agreement by Licensee. 
 ARTICLE VI 

Diligence; Minimum Royalties 
 Licensee shall undertake to use commercially reasonable and diligent efforts for a company of Licensee’s size and resources, directly or through a sublicensee, to develop or commercialize one or more
Licensed Products, including its first Licensed Product by 2016 and a second Licensed Product by 2018. Licensee will be considered not to have utilized reasonable commercial efforts unless it (or a sublicensee) makes the following minimum annual
royalty payments to Licensor: 
  

	 	(a)	[***]; 

  

	 	(b)	[***]; and 

  

	 	(c)	[***]. 

 Such payments will be creditable
against earned royalties otherwise due to Licensor for a given calendar year. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 ARTICLE VII 
 Protection of Patents 
 7.1 Protection. Each party agrees to
cooperate fully in any action under this Article VII which is controlled by the other party, including by joining as a party to any proceeding if required by applicable law; provided that the controlling party reimburses the cooperating party
promptly for any reasonable costs and expenses incurred by the cooperating party in connection with providing such assistance. [***] 
 7.2 Notice of Infringement; Licensor Enforcement of Third Party Infringement. Licensor and Licensee shall each give prompt written notice to the other of any infringement of a Licensed Patent by
any third party as may come to its knowledge. [***] 
 7.3 Notice of Infringement; Claim of Licensee Infringement.
Licensee shall promptly advise Licensor in writing of any notice or claim of any infringement and of the commencement against it of any suit or action for infringement of a third party patent made or brought against Licensee and based upon the use
hereunder by Licensee of the Licensed Patents. [***] 
  

	 	(a)	[***] 

  

	 	(b)	[***] 

 7.4 Reasonable
Assistance. [***] 
 7.5 Declaratory Judgment Actions. If a declaratory judgment action is brought naming Licensor or
Licensee or any of its Affiliates or sublicensees as a defendant and alleging invalidity, unenforceability or non-infringement of any Licensed Patents, Licensee or Licensor, as the case may be, shall promptly notify the other party in writing. [***]

 7.6 Patent Certifications. Each party shall notify and provide the other with copies of any allegations of alleged
patent invalidity, unenforceability or non-infringement of a Licensed Patent pursuant to the FDA’s Paragraph IV Patent Certification procedure by a third party filing an Abbreviated New Drug Application, an application under §505(b)(2) of
the Federal Food, Drug and Cosmetics Act, or any other similar patent certification by a third party, and any foreign equivalent thereof. Such notification and copies shall be provided to the other party within five (5) business days after the
party receives such certification. 
 ARTICLE VIII 
 Disclaimer of Liability and/or Warranty 
 8.1 No Warranty. Nothing
in this Agreement shall be construed as: 
  

	 	(a)	a warranty or representation by Licensor as to the validity or scope of any Licensed Patents; or 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

	 	(b)	a warranty or representation that anything Made, Used or Sold under any license granted in this Agreement is or will be free from infringement of patents, copyrights,
and/or trademarks of third parties; or 

  

	 	(c)	an express or implied warranty of merchantability or fitness for a particular purpose. 

8.2 No Damages. Neither party shall be liable to the other party for indirect, special, consequential or punitive damages under
any circumstances. 
 8.3 No Warranty of Quality or Usefulness. Licensor shall have no responsibility for the ability of
Licensee to use such information, the quality or performance of any process or any Licensed Product produced by Licensee with the aid of such information, or with respect to claims of third parties arising from Licensee’s use of such
information. 
 8.4 Indemnification. Licensee shall assume all responsibility and liability for the sale, use,
production, and/or commercialization of the Licensed Products, including, but not limited to, the safety, effectiveness, and reliability of the Licensed Products produced pursuant to this Agreement. Licensee further agrees to defend, indemnify, and
hold harmless Licensor, its trustees, directors, officers, employees, agents, representatives, successors, assigns, affiliated entities and Other Corporations (as defined in Section 11.3 below) (collectively “Indemnitees’’) from
and against any and all liability, demands, damages, expenses and losses for death, personal injury, illness, or property damage, including the cost of defense against same, which may be asserted by third parties, or any third party claims which may
arise from the sale, use, production, commercialization, or other disposition of Licensed Products pursuant to any right or license granted under this Agreement, except to the extent that such liability, demands, damages, expenses or losses relate
to or arise out of Licensor’s material breach of its representations, warranties and covenants under this Agreement, or Licensor’s or Indemnitees’ gross negligence or willful misconduct. 

8.5 Insurance. Licensee agrees to purchase and/or maintain insurance coverage sufficient, taking into account its other assets, to
establish the ability of Licensee to honor the indemnity made herein, and Licensor shall be listed as an additional named insured on any such insurance coverage. Licensee shall furnish evidence satisfactory to Licensor of its insurance coverage upon
request of Licensor. Upon Licensee’s, or any of its sublicensees’, Making, Use or Sale of Licensed Products commercially, the initial amount of insurance coverage required is in the face amount of [***]. 

ARTICLE IX 

Term; Termination 
 9.1 Term. The Term of this Agreement (“Term”) shall continue until its expiration upon the later of: (a) there being no more Valid Claims within the Licensed Patents, or (b) the
expiration of Licensee’s royalty obligations on Licensed Products that are subject to an earned royalty, if such earned royalty is based on the minimum ten (10) year royalty period described in Section 4.2(b) above; unless this
Agreement is earlier terminated as herein provided. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 9.2 Termination for Cause; Insolvency. If Licensee shall determine that it
intends to file for bankruptcy or reorganization, it shall give prompt written notice to Licensor. Failure to give such notice shall cause immediate termination of this Agreement, and all rights of Licensee in the Licensed Patents shall
automatically revert to Licensor. If Licensee shall become bankrupt; if the business or any assets or property of Licensee shall be placed in the hands of a receiver, assignee or trustee, whether by the voluntary act of Licensee or otherwise; if
Licensee institutes or suffers to be instituted any procedure in bankruptcy court for reorganization or rearrangement of its financial affairs; if Licensee makes a general assignment for the benefit of creditors; or if Licensee or an Affiliate or a
sublicensee (with the assistance, consent, approval or cooperation of Licensee) institutes or suffers to be instituted any procedure, administratively or in a court, challenging validity or patentability of any patent or patent application within
the Licensed Patents, this Agreement shall immediately terminate, and all rights of Licensee in the Licensed Patents shall automatically revert to Licensor. Upon occurrence of any of the foregoing events, Licensee shall give prompt written notice
thereof to Licensor. 
 9.3 Default. Upon any breach or default under this Agreement by Licensee, Licensor may give
written notice thereof to Licensee, and Licensee shall have ninety (90) days thereafter to cure such breach or default, except in the event of a breach or default by non-payment, in which case the cure period shall be thirty (30) days. If
such breach or default is not cured within such period, Licensor shall have the right in its sole option to cancel and terminate this Agreement and the licenses granted by it by giving written notice thereof to Licensee. In such event, Licensor may
also seek such other relief as may be provided by law or in equity in such circumstances. 
 9.4 Commercialization Rights
Upon Termination. Upon termination hereof under Section 9.2 or 9.3, all rights of Licensee in the Licensed Patents shall revert to Licensor, and Licensee agrees to execute appropriate written releases and/or assignments of such rights to
Licensor; and further, Licensee agrees to discontinue the commercialization of the Licensed Patents. Upon expiration of the Term and Licensee’s payment of all amounts due Licensor hereunder, Licensee will continue to have commercialization
rights with respect to the Licensed Products with no further royalty obligation to Licensor, and Licensor will not license or otherwise grant rights to any third party inconsistent with such rights remaining exclusively in Licensee. 

9.5 Provisions Surviving Termination. Articles X and XIII and Sections 8.1, 8.2, 8.3, 8.4, 9.4 and 11.3 of this Agreement shall
survive expiration or termination of this Agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 ARTICLE X 
 Representations and Warranties 
 10.1 Warranty to Title. Licensor
represents and warrants that it owns the Licensed Patents and has the legal power and authority to extend the rights granted to Licensee pursuant to this Agreement, and that it has not assigned, licensed, pledged or compromised the Licensed Patents
or made any commitments or offers inconsistent with or in derogation of the rights created by this Agreement. 
 10.2 Power
and Authority. Licensee represents and warrants that (a) it has full power and authority to enter into this Agreement and to carry out the transactions contemplated hereby; and (b) this Agreement constitutes the legal, valid and
binding obligation of Licensee, enforceable against Licensee in accordance with its terms. 
 10.3 Compliance with Laws.
Licensee represents and warrants that it will comply with all applicable laws and regulations, including without limitation, all United States laws and regulations controlling the export of commodities and technical data. Licensee will be solely
responsible for any violation of such laws or regulations by Licensee, and it will defend and hold Licensor harmless in the event of any legal action of any nature occasioned by such violation. 

10.4 No Knowledge of Infringement. Licensor represents that it has no knowledge of any infringement of the Licensed Patents by any
third party. 
 ARTICLE XI 
 Agency/Partnership/Use of Name 
 11.1 No Agency. Neither party shall
be deemed to be an agent of the other party as a result of any transaction under or related to this Agreement, and shall not in any way pledge the other party’s credit or incur any obligations on behalf of the other party. 

11.2 No Partnership. This Agreement shall not constitute either a partnership or a joint venture, and neither party may be bound
by the other to any contract, arrangement or understanding except as specifically stated herein. 
 11.3 Prohibition Against
Use of Name. Except to the extent required to comply with applicable laws and regulations, without prior written consent obtained from Licensor, Licensee (including any Affiliate or sublicensee of Licensee) shall not use for purposes of sales,
advertising, marketing, marking of goods, promotion to investors, press releases or other publicity, etc.: (i) the name of (or any other information which would identify) Licensor or any corporation which is controlled by the same persons who
control Licensor (“Other Corporation”); (ii) the names of trustees, directors, officers, or employees of Licensor or an Other Corporation; or (iii) any trademarks (or adaptations thereof) of Licensor or an Other Corporation. The
foregoing notwithstanding, without the consent of Licensor, Licensee may 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
indicate other than in advertising that it is licensed by Licensor under the Licensed Patents and identify the inventors, their affiliation with Licensor, and their relationship to Licensor, and
further, Licensee may comply with disclosure requirements of all applicable laws relating to its business, including, without limitation, United States and state securities laws. 

ARTICLE XII 

Marking 

To the extent commercially feasible and consistent with prevailing business practices, Licensee agrees to apply or have applied to all
articles and to all containers containing Licensed Products manufactured by it or any sublicensee(s) under this Agreement the number of each issued patent under the Patent Rights that applies to such Licensed Product. 

ARTICLE XIII 

Nondisclosure of Confidential Information 
 All confidential or proprietary business, scientific and technical information communicated by one party to the other party under this Agreement, including information contained in unpublished patent
applications, shall be kept confidential by such other party. Notwithstanding the foregoing, either party shall be relieved of the confidentiality obligations herein and not be prevented by this Agreement from utilizing any information received by
it from the other party if: 
  

	 	(a)	the information, at the time of disclosure, is in the public domain or, after disclosure, becomes part of the public domain through no act or omission of the receiving
party; 

  

	 	(b)	the receiving party can show that the information was in its possession at the time of disclosure and was not acquired, directly or indirectly, from the disclosing
party; 

  

	 	(c)	the information is lawfully obtained or received on a non-confidential basis from a third party, other than the disclosing party, having the legal right to transmit
same; or 

  

	 	(d)	the disclosure of such information is essential for the commercial exploitation of the Licensed Patents under this Agreement, provided that such information is
disclosed subject to a secrecy agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 ARTICLE XIV 
 Miscellaneous 
 14.1 Captions. The captions herein are for
convenience only and shall not be deemed to limit or otherwise affect the construction hereof. 
 14.2 Notices. Any
notice or other communication hereunder must be given in writing and (a) delivered in person, (b) transmitted by telefax or other telecommunications mechanism, (c) mailed by certified or registered mail, postage prepaid, receipt
requested, or (d) sent by overnight delivery with charges prepaid and receipt acknowledged, as follows: 
 If to Licensor,
addressed to: 
 Research Development Foundation 
 402 North Division Street 
 Carson City, Nevada 89703 

   Attn:  Andrew MacKenzie, Esq. 
 Phone:  (775) 882-0202 
 Fax:  (775) 882-7918

 If to Licensee, addressed to: 
 bluebird bio, inc. 
 840 Memorial Drive 

Cambridge, Massachusetts 02139 
    Attn:  Head of Business Development 

Phone:  (617) 873-0900 
 Fax:  (617) 576-2421 
 or to such other address or to such other
person as the party shall have last designated by such notice to the other party. Each such notice or other communication shall be effective when actually received at such address. 

14.3 Assignment. This Agreement, in whole or in part, shall not be assignable by either party without prior written consent of the
other party (unless to a successor entity to such party by merger, acquisition, consolidation or other non-bankruptcy reorganization or sale of substantially all of its assets or that portion of its business to which this Agreement relates), and any
attempted assignment without such consent shall be void. 
 14.4 No Waiver. The failure of either party to enforce at any
time any of the provisions of this Agreement, or any rights in respect thereto, or to exercise any election herein provided, shall in no way be considered to be a waiver of such provisions, rights, or elections, or in any way to affect the validity
of this Agreement. The exercise by either party of any of its rights herein or any of its elections under the terms or covenants herein shall not preclude either party from exercising the same or any other rights it may have under this Agreement,
irrespective of any previous action or proceeding taken by either party hereunder. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 14.5 Choice of Law and Jurisdiction. This Agreement shall be governed and
construed in accordance with the laws of the State of Nevada, U.S.A. applicable to contracts made in such State without regard to conflicts of law doctrines, and the parties agree that jurisdiction and venue for any dispute regarding this Agreement
will be in such State. 
 14.6 Severability. If any provision of this Agreement is judicially determined to be void or
unenforceable, such provision shall be construed to be severable from the other provisions of this Agreement, which shall retain full force and effect. 
 14.7 Further Acts. The parties hereto agree promptly to execute, forward, or otherwise provide all documents and material necessary or desirable to effectuate this Agreement. 

14.8 Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter
hereof and shall supersede all previous communications, either oral or written, between the parties hereto with respect to the subject matter hereof. No agreement or understanding bearing on the same shall be binding upon either party hereto unless
it shall be in writing and signed by the duly authorized officer or representative of each of the parties and shall expressly refer to this Agreement. 
 14.9 Successors and Assigns. This Agreement shall be binding on and shall inure to the benefit of the parties hereto, and their respective successors and assigns. 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed in multiple originals by their duly authorized
representatives. 
  

			
	RESEARCH DEVELOPMENT FOUNDATION
		
	By:	 	 /s/ Andrew MacKenzie

		
	Print Name:	 	 Andrew MacKenzie

		
	Title:	 	 Vice President

	
	BLUEBIRD BIO, INC.
		
	By:	 	 /s/ Nick Leschly

		
	Print Name:	 	 Nick Leschly

		
	Title:	 	 CEO

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 EXHIBIT 1 
 Licensed Patents 
 [See attached insert from F&J Master Listings] 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

			
	

	  	Research Development Foundation by Alias
	  	  
 Master Listing of
Technologies

	  	  
 10/04/2011

  

			
	CLFR: 010	  	 TITLE: [***]
 Summary:
[***]

 Client Reference No.: NULL 
 [***] 
  

													
	 Country
	  	 Case
	  	 Status
	  	 Application No.
	  	 Filing Date
	  	 Patent No.
	  	 Granted

	 [***]
	  		  		  		  		  		  	

  

			
	CLFR: 011	  	 TITLE: [***]
 Summary:
[***]

 Client Reference No.: CLFR:011 
 [***] 
  

													
	 Country
	  	 Case
	  	 Status
	  	 Application No.
	  	 Filing Date
	  	 Patent No.
	  	 Granted

	 [***]
	  		  		  		  		  		  	

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

			
	

	  	Research Development Foundation by Alias
	  	  
 Master Listing of
Technologies

	  	  
 10/04/2011

  

			
	CLFR: 014	  	 TITLE: [***]
 Summary:
[***]

 Client Reference No.: NULL 
 [***] 
  

													
	 Country
	  	 Case
	  	 Status
	  	 Application No.
	  	 Filing Date
	  	 Patent No.
	  	 Granted

	 [***]
	  		  		  		  		  		  	

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 EXHIBIT 2 
 Milestone Payments 
 Except as provided herein, milestone payments in the
following amounts shall be paid for each Licensed Product requiring marketing approval, payable on a product-by-product basis: 

[***] 
 Each
milestone shall be payable one time only, on a Licensed Product-by-Licensed Product basis. 
 In the event that a Licensed
Product achieves the milestone on more than one occasion, only the first achievement of such shall be subject to milestone consideration. For example, [***].EX-10.10

 Exhibit 10.10 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 NOVATION AGREEMENT 
 This Agreement between THE BOARD
OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and bluebird bio, Inc., a corporation having a principal place of business at
840 Memorial Drive, Cambridge, MA 02139 is effective on the 2nd day of April, 2012 (“Effective Date”). 
  

	 	1	BACKGROUND 

 Stanford has
rights to biological material known as 293T Cell Line. It was developed in the laboratory of Dr. Michele Calos, and is described in Stanford Docket S97-079. The biological material was developed in the course of research supported by the
National Institutes of Health. Stanford wants to have the biological material developed and marketed as soon as possible so that resulting products may be available for public use and benefit. 

Stanford and BBB (formerly Genetix Pharmaceuticals Inc.) are parties to a previous agreement concerning the Biological Material dated
July 11, 2002, hereafter “Prior Agreement”. Stanford and BBB wish to amend and restate said Prior Agreement by this Novation Agreement (“Agreement”), beginning as of the Effective Date of this Agreement. 

 

	 	2	DEFINITIONS 

  

	 	2.1	“BBB” means bluebird bio, Inc. and its Affiliates. “Affiliates” any person, corporation, or other business entity which controls, is controlled by,
or is under common control with BBB; and for this purpose, “control” of a corporation means the direct or indirect ownership of more than fifty percent (50%) of its voting stock, and “control” of any other business entity
means the direct or indirect ownership of greater than a fifty percent (50%) interest in the income of such entity. 

  

	 	2.2	“Biological Material” means the 293T cell line previously provided to BBB under the Prior Agreement. 

 

	 	2.3	“Licensed Field of Use” means any commercial and/or non-commercial use of Biological Material for: 

 

	 	•	 	 research, and non-clinical and clinical development purposes; and 

 

	 	•	 	 human and animal gene therapy products. 

  

	 	2.4	“Licensed Product” means a product or part of a product in the Licensed Field of Use containing, derived from, or made using Biological Material.

  

	 	2.5	“Licensed Territory” means [***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

	 	2.6	“Net Sales” means all gross revenue actually received by BBB, from the sale, transfer or disposition of Licensed Product to a third party. Net Sales excludes
the following items (but only as they pertain to the making, using, importing or selling of Licensed Products, are included in gross revenue, and are separately billed): 

 

	 	(A)	import, export, excise and sales taxes, and custom duties; 

  

	 	(B)	costs of insurance, packing, and transportation from the place of manufacture to the customer’s premises or point of installation; 

 

	 	(C)	credit for returns, allowances, or trades; and 

  

	 	(D)	cash, trade or quantity discounts actually granted to third parties. 

 For clarity, Net Sales does not include (i) any payments received by BBB, its affiliates, or sublicensees in consideration of a Sublicense; or (ii) transfers of a Licensed Product between any of
BBB, an affiliate or a sublicensee for sale by the transferee. 
  

	 	2.7	“Stanford Indemnitees” means Stanford and Stanford Hospitals and Clinics, and their respective trustees, officers, employees, students, and agents.

  

	 	3	GRANT 

  

	 	3.1	Grant. Subject to the terms and conditions of this Agreement, Stanford hereby grants BBB a license under the Biological Material in the Licensed Field of Use to
make, have made, use, have used, import, have imported, offer to sell, have offered to sell, sell and have sold Licensed Product in the Licensed Territory. 

 

	 	3.2	Nonexclusivity. The license is nonexclusive in the Licensed Field of Use beginning on April 2, 2012 and expiring April 2, 2037. BBB may elect to extend
the term of this Agreement for additional twenty five (25) year periods upon written notice to Stanford, without further consideration or amendment to this agreement; provided however, that i) such notice of extension must include verification
by BBB that it has a commercial product on the market at that time, and ii) BBB is in material compliance with this Agreement at that time. If either of these conditions is not met, BBB and Stanford may elect to extend the term of this Agreement by
mutual consent. 

  

	 	3.3	Retained Rights. Stanford retains title to all Biological Materials. 

 

	 	3.4	Specific Exclusion. Stanford does not: 

  

	 	(A)	grant to BBB any other licenses, implied or otherwise, to any patents or other rights of Stanford regardless of whether the patents or other rights are required to
exploit any Biological Material; and 

  

	 	(B)	agree to furnish to BBB any technology or technological information other than the Biological Material or to provide BBB with any assistance. 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

	 	4	SUBLICENSING 

  

	 	4.1	Permitted Sublicensing. BBB may grant sublicenses to its rights under this Agreement in the Licensed Field of Use to third parties. Such Sublicensees may then
grant further sublicenses to other third parties for the purpose of the development, manufacturing, marketing, selling, importing and distribution of Licensed Products; provided however that (i) Sublicensees shall first submit to Stanford the
identity of such other third party, along with a summary of the purpose for such further sublicense and (ii) Stanford shall then provide Sublicensee its prompt, prior written consent, which shall not be unreasonable withheld or conditioned.

  

	 	4.2	Sublicense Requirements. Any Sublicense: 

  

	 	(A)	is subject to this Agreement; 

  

	 	(B)	will expressly include the provisions of Articles 8, 9, and 10 for the benefit of Stanford; and 

 

	 	(C)	will require the transfer of all the sublicensee’s obligations to BBB specifically relating to the sublicense, including the payment of royalties related to the
Biological Material specified in the sublicense, to Stanford or its designee, if this Agreement is terminated. 

  

	 	(D)	BBB will submit to Stanford a copy of each sublicense promptly following execution. 

 

	 	4.3	Sublicense Consideration. BBB will pay Stanford a [***] payment in consideration of said sublicense, unless such sublicense is to a collaborating partner,
contract manufacturer or contract research organization during the term of the agreement between BBB and such partner/contractor. If sublicensee already has a license for the research use of the Biological Material, said milestone payment will be
reduced to [***]. If the sublicensee already has a license for the commercial use of the Biological Material, said milestone payment will not be due. 

  

	 	5	GOVERNMENT RIGHTS 

 This
Agreement is subject to Title 35 Sections 200-204 of the United States Code. Among other things, these provisions provide the United States Government with nonexclusive rights to the Biological Material. BBB will ensure all obligations of these
provisions are met. 
  

	 	6	ROYALTIES 

  

	 	6.1	Issue Royalty. BBB will pay to Stanford a noncreditable, nonrefundable license issue royalty of [***] within thirty (30) days after signing this Agreement.
Upon receipt of payment, Stanford will send Biological Material to BBB. 

  

	 	6.2	License Maintenance Fee. Beginning April 2, 2013, and each April 2, thereafter, BBB will pay Stanford a yearly license maintenance fee based on the Net
Sales of Licensed Products as follows: 

 [***]; 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 [***] 
 [***] 
 [***] 

Yearly maintenance payments are nonrefundable, but they are creditable each year as described in Section 6.4. 

 

	 	6.3	Earned Royalty. BBB will pay Stanford earned royalties on Net Sales as follows: 

Licensed Products for Research Use [***] of Net Sales 
 Licensed Products for human and animal lentivirus based gene therapy products: 

[***] 
 [***]

 These percentages shall be reduced by [***] for each third party license that requires payment(s) by BBB with respect to a
Licensed Products; provided however, the royalty owed to Stanford under this Section 6.3 shall not be less than [***] on this basis. 
  

	 	6.4	Creditable Payments. The license maintenance fee for a year may be offset against earned royalty payments due on Net Sales occurring in that year.

 For example: 
  

	 	(A)	if BBB pays Stanford a $10 maintenance payment for year Y, and according to Section 6.3 $15 in earned royalties are due Stanford for Net Sales in year Y, BBB will
only need to pay Stanford an additional $5 for that year’s earned royalties due on Net Sales. 

  

	 	(B)	if BBB pays Stanford a $10 maintenance payment for year Y, and according to Section 6.3 $3 in earned royalties are due Stanford for Net Sales in year Y, BBB will
not need to pay Stanford any earned royalty payment due on Net Sales for that year. BBB will not be able to offset the remaining $7 against a future year’s earned royalties. 

 

	 	6.5	No Escrow. BBB shall not pay royalties into any escrow or other account. 

 

	 	6.6	Currency. BBB will calculate the royalty on sales in currencies other than U.S. Dollars using the appropriate foreign exchange rate for the currency quoted by
the Bank of America (San Francisco) foreign exchange desk, on the close of business on the last banking day of each calendar quarter. BBB will make royalty payments to Stanford in U.S. Dollars. 

 

	 	6.7	Non-U.S. Taxes. BBB will pay all non-U.S. taxes related to royalty payments. These payments are not deductible from any payments due to Stanford.

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

	 	6.8	Interest. Any payments not made when due will bear interest at the lower of (a) [***] or (b) the maximum rate permitted by law.

  

	 	7	ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING 

  

	 	7.1	Earned Royalty Payment and Report. Beginning with the first commercial sale of a Licensed Product to a third party, BBB will submit to Stanford a written report
(even if there are no commercial sales) and an earned royalty payment within sixty (60) days after the end of each calendar year [***], and within sixty (60) days after the end of each calendar quarter thereafter. This report will be in
the form of Appendix A and will state the number, description, and aggregate Net Sales of Licensed Product during the completed calendar quarter. With each report BBB will include any earned royalty payment due Stanford for the completed calendar
quarter (as calculated under Section 6.3 and subject to Section 6.4.) 

  

	 	7.2	Termination Report. BBB will pay to Stanford all applicable royalties and submit to Stanford a written report within ninety (90) days after the license
terminates. BBB will continue to submit earned royalty payments and reports to Stanford after the license terminates, until all Licensed Products made or imported under the license have been sold. 

 

	 	8	EXCLUSIONS AND NEGATION OF WARRANTIES 

  

	 	8.1	Representation. Stanford represents that it has the right to enter into this Agreement and grant the rights and licenses hereunder. 

 

	 	8.2	Negation of Warranties. Except as provided in Section 8.1, Stanford provides BBB the rights granted in this Agreement AS IS and WITH ALL FAULTS. Stanford
makes no representations and extends no warranties of any kind, either express or implied. Among other things, Stanford disclaims any express or implied warranty: 

 

	 	(A)	of merchantability, of fitness for a particular purpose, 

  

	 	(B)	of non-infringement or 

  

	 	(C)	arising out of any course of dealing. 

  

	 	8.3	No Representation of Biological Material. BBB also acknowledges that Stanford does not represent or warrant that the exploitation of Biological Material will be
successful. 

  

	 	9	INDEMNITY 

  

	 	9.1	Indemnification. BBB will indemnify, hold harmless, and defend all Stanford Indemnitees against any third party claim of any kind arising out of or related to
the exercise of any rights granted BBB under this Agreement or the breach of this Agreement by BBB. 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

	 	9.2	No Indirect Liability. Neither party will be liable to the other for any indirect, special, consequential, or other damages whatsoever, whether grounded in tort
(including negligence), strict liability, contract, or otherwise arising out of or in connection with solely this Agreement under any theory of liability, provided, however, that the foregoing will not apply to any right of action for infringement,
contributory infringement or inducement of infringement Stanford may have under any applicable law. Stanford will not have any responsibilities or liabilities whatsoever with respect to Licensed Product(s). 

 

	 	9.3	Workers’ Compensation. BBB will comply with all statutory workers’ compensation and employers’ liability requirements for activities performed
under this Agreement. 

  

	 	9.4	Insurance. During the term of this Agreement, BBB will maintain Comprehensive General Liability Insurance, including Product Liability Insurance, with a
reputable and financially secure insurance carrier to cover the activities of BBB. The insurance will provide minimum limits of liability of [***]. Insurance must cover claims incurred, discovered, manifested, or made during or after the expiration
of this Agreement and must be placed with carriers with ratings of at least A- as rated by A.M. Best. Within 15 days of the Effective Date of this Agreement, BBB will furnish a Certificate of Insurance evidencing primary coverage and additional
insured requirements. BBB will provide to Stanford 30 days prior written notice of cancellation or material change to this insurance coverage. BBB will advise Stanford in writing that it maintains excess liability coverage (following form) over
primary insurance for at least the minimum limits set forth above. All insurance of BBB will be primary coverage; insurance of Stanford and Stanford Hospitals and Clinics will be excess and noncontributory. 

 

	 	10	STANFORD NAMES AND MARKS 

BBB will not identify Stanford in any promotional statement, or otherwise use the name of any Stanford faculty member, employee, or
student, or any trademark, service mark, trade name, or symbol of Stanford or Stanford Hospitals and Clinics, including the Stanford name, unless BBB has received Stanford’s prior written consent. Permission may be withheld at Stanford’s
sole discretion. Notwithstanding the foregoing, without the consent of Stanford, BBB may state to its actual and prospective investors, strategic partners and sublicensees that it is licensed under the Biological Material, and further BBB may comply
with disclosure requirements of all applicable laws relating to its business, including, without limitation, United States and state securities laws. 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

	 	11	TERMINATION 

  

	 	11.1	Termination by BBB. 

  

	 	(A)	BBB may terminate this Agreement by giving Stanford written notice at least 30 days in advance of the effective date of termination selected by BBB.

  

	 	(B)	As of the effective date of termination, BBB will: 

  

	 	(1)	cease use and sale of Biological Material and any Licensed Products; and 

  

	 	(2)	return to Stanford or destroy all Biological Material. 

  

	 	11.2	Termination by Stanford. 

  

	 	(A)	Stanford may also terminate this Agreement if BBB: 

  

	 	(1)	is delinquent on any report or payment; 

  

	 	(2)	is not using commercially reasonable efforts to develop, manufacture and/or commercialize one or more Licensed Products or to enter into a partnering or collaboration
agreement or corporate transaction with respect to Licensed Products; 

  

	 	(3)	is in material breach of any provision; or 

  

	 	(4)	provides any false report. 

  

	 	(B)	Termination under this Section 11.2 will take effect 30 days after written notice by Stanford unless BBB remedies the problem in that 30-day period, except for
Sections 11.2(A)(2), in which case termination will take place 120 days after written notice by Stanford unless BBB remedies the problem in that 120-day period. 

 

	 	(C)	As of the effective date of termination, BBB will: 

  

	 	(1)	cease use and sale of Biological Material and any Licensed Products; and 

  

	 	(2)	return to Stanford or destroy all Biological Material. 

  

	 	11.3	Surviving Provisions. Surviving any termination or expiration are: 

  

	 	(A)	BBB’s obligation to pay royalties accrued or accruable; 

  

	 	(B)	any claim of BBB or Stanford, accrued or to accrue, because of any breach or default by the other party; and 

 

	 	(C)	the provisions of Articles 6.4, 7, 8, and 9, and any other provision that by its nature is intended to survive. 

 

	 	12	ASSIGNMENT 

 The rights
and obligations of the parties under this Agreement may not be assigned or otherwise transferred without the written consent of Stanford and BBB; however, no consent is needed for an assignment to an entity which acquires a party (which

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 
acquisition may be by merger, purchase of assets, or change of control), so long as the acquiring entity agrees in writing to be bound by the terms of this Agreement. In the event of any
acquisition of BBB, Stanford agrees to execute whatever agreements are necessary, if any, to assure the transfer of the rights and obligations herein to the succeeding entity. 

 

	 	13	EXPORT 

 BBB and its
affiliates and sublicensees shall comply with all United States laws and regulations controlling the export of licensed commodities and technical data. (For the purpose of this paragraph, “licensed commodities” means any article, material
or supply but does not include information; and “technical data” means tangible or intangible technical information that is subject to US export regulations, including blueprints, plans, diagrams, models, formulae, tables, engineering
designs and specifications, manuals and instructions.) These laws and regulations may include, but are not limited to, the Export Administration Regulations (15CFR 730-774), the International Traffic in Arms Regulations (22 CFR 120-130) and the
various economic sanctions regulations administered by the US Department of the Treasury (31 CFR 500-600). 
 Among other things,
these laws and regulations prohibit or require a license for the export or retransfer of certain commodities and technical data to specified countries, entities and persons. BBB hereby gives written assurance that it will comply with, and will cause
its affiliates and sublicensees to comply with all United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its affiliates or sublicensees, and that it will
indemnify, defend and hold Stanford harmless for the consequences of any such violation. 
  

	 	14	ARBITRATION 

 Any dispute
between the parties regarding any payments made or due under this Agreement will be settled by arbitration in accordance with the JAMS Arbitration Rules and Procedures. The parties are not obligated to settle any other dispute that may arise under
this Agreement by arbitration. 
  

	 	15	NOTICES 

 All notices
under this Agreement are deemed fully given when written, addressed, and sent as follows: 
 All general notices to BBB are
mailed to: 
 Head of Business Development 

Bluebird Bio, Inc. 
 840 Memorial Drive. 
 Cambridge, MA 02139 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 All financial invoices to BBB (i.e., accounting contact) are e-mailed to: 

[***] 
 With a copy to: [***] 
 All progress report invoices to BBB (i.e., technical
contact) are e-mailed to: 
 [***] 
 All general notices to Stanford are e-mailed or mailed to: 

Office of Technology Licensing 
 1705 El Camino Real 
 Palo Alto, CA 94306-1106 

[***] 
 All payments to Stanford are mailed to: 
 Stanford University

 Office of Technology Licensing 

Department #44439 
 P.O. Box 44000 
 San Francisco, CA 94144-4439 

All progress reports to Stanford are e-mailed or mailed to: 

Office of Technology Licensing 
 1705 El Camino Real 
 Palo Alto, CA 94306-1106 

[***] 
 Either party may change its address with written notice to the other party. 
  

	 	16	MISCELLANEOUS 

  

	 	16.1	Waiver. No term of this Agreement can be waived except by the written consent of the party waiving compliance. 

 

	 	16.2	Choice of Law. This Agreement and any dispute arising under it is governed by the laws of the State of California, United States of America, applicable to
agreements negotiated, executed, and performed within California, without reference to its conflicts of laws principles. 

  

	 	16.3	 Exclusive Forum. Subject to Section 14, the state and federal courts having jurisdiction over Stanford, California, United States of
America, provide the 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

	 	
exclusive forum for any court action between the parties relating to this Agreement. BBB submits to the jurisdiction of such courts, and waives any claim that such a court lacks jurisdiction over
BBB or constitutes an inconvenient or improper forum. 

  

	 	16.4	Headings. No headings in this Agreement affect its interpretation. 

  

	 	16.5	Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for
which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature.

 The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives.

  

					
	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
			
		 	Signature:	 	 /s/ Katharine Ku

			
		 	Name:	 	 Katharine Ku

			
		 	Title:	 	 Director, Technology Licensing

			
		 	Date:	 	 April 12, 2012

	
	BLUEBIRD BIO
			
		 	Signature:	 	 /s/ Nick Leschly

			
		 	Name:	 	 Nick Leschly

			
		 	Title:	 	 Chief Executive Officer

			
		 	Date:	 	 4/2/12

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 APPENDIX A 
 SAMPLE REPORTING FORM 
 Stanford Docket No. S97-079 

This report is provided pursuant to the license agreement between Stanford University and bluebird bio, Inc. 

License Agreement Effective Date: April 2, 2012 
  

			
	Report Covering Period	  	
	Yearly Maintenance Fee	  	$            
	Net Sales	  	$
	Royalty Calculation	  	
	Royalty Subtotal	  	$
	Credit	  	$
	Royalty Due	  	$

 Comments:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]